Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Apr 14;8(10):879–887. doi: 10.1158/1940-6207.CAPR-14-0324

Table 2a.

Diagnosis of Prostate Cancer by treatment arm of men with baseline diagnosis of HGPIN and ASAP (N=97)

Treatment Total subjects Censored** due to AE before 6 months (N) PCa at 6 months (N) Censored** due to AE between 6–12 months (N) PCa at 12 months (N) Censored** at 12 months (N) Total PCa events Log-rank P value*
Placebo 48 12 3 1 6 26 9 0.25
Polyphenon E 49 14 1 1 4 29 5
Total 97 26 4 2 10 55 14
*

The log-rank test is an overall comparison on the diagnosis of PCa, as a time-to-event endpoint.

**

Censored patients due to AEs.